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In this study,wedemonstrate that, amongall fiveCBX
Polycomb proteins, only CBX7 possesses the ability
to control self-renewal of human hematopoietic
stem and progenitor cells (HSPCs). Xenotransplanta-
tion of CBX7-overexpressing HSPCs resulted in
increased multi-lineage long-term engraftment and
myelopoiesis. Gene expression and chromatin ana-
lyses revealed perturbations in genes involved in
differentiation, DNA and chromatin maintenance,
and cell cycle control. CBX7 is upregulated in acute
myeloid leukemia (AML), and its genetic or pharma-
cological repression in AML cells inhibited prolifera-
tion and induced differentiation. Mass spectrometry
analysis revealed several non-histone protein inter-
actions between CBX7 and the H3K9 methyltrans-
ferases SETDB1, EHMT1, and EHMT2. These CBX7-
binding proteins possess a trimethylated lysine
peptide motif highly similar to the canonical CBX7
target H3K27me3. Depletion of SETDB1 in AML cells
phenocopied repression of CBX7. We identify CBX7
as an important regulator of self-renewal anduncover
non-canonical crosstalk between distinct pathways,
revealing therapeutic opportunities for leukemia.
INTRODUCTION
Hematopoietic stem cells (HSCs) are able to self-renew and
differentiate into all mature blood cells to ensure peripheral blood
cell homeostasis during an adult lifespan. In these primitive
cells, the choice between self-renewal and differentiation must
be well balanced to avoid either cytopenia or hyperproliferative
conditions, such as leukemia. Self-renewal and differentiation
are accompanied and controlled by a multitude of epigenetic1906 Cell Reports 26, 1906–1918, February 12, 2019 ª 2019 The Aut
This is an open access article under the CC BY-NC-ND license (http://changes of DNA and of histone proteins (Kamminga et al.,
2006; Klauke et al., 2013; Rizo et al., 2008; Tadokoro et al.,
2007). One important family of epigenetic regulators that is crit-
ical for stem cells is represented by the Polycomb group (PcG)
genes.
PcG genes encode for chromatin-associated proteins, which
assemble in various multimeric protein complexes and
contribute to the regulation of gene expression patterns by post-
translational modifications of histone tails (Bracken et al., 2006;
Cao et al., 2005).
The two best-characterized PcG protein complexes are the
canonical polycomb repressive complex 1 (PRC1) and PRC2.
The canonical PRC1 is characterized by the presence of at least
one of the five Polycomb chromobox proteins (CBX2, 4, 6, 7, and
8). Many functional and molecular studies have shown similar
and overlapping binding patterns of PRC1- and PRC2-protein-
containing complexes (Comet and Helin, 2014; Morey et al.,
2012). Although the enzymatic activity of many individual epige-
netic writers and erasers has been elucidated, our understanding
of the biological role and the molecular dynamics of epigenetic
protein complexes is still limited.
CBX proteins are characterized as chromodomain-containing
proteins, recognizing trimethylated lysine 27 on histone H3
(H3K27me3), which is deposited by EZH1 and EZH2 (Fischle
et al., 2003; Min et al., 2003). After recognition of H3K27me3
by the CBX proteins, the catalytic subunit of PRC1, RING1A
and/or RING1B, ubiquitinates H2AK119 (Cao et al., 2005), lead-
ing to the repression of transcription through chromatin
compaction and inhibition of RNA Polymerase 2 (Stock et al.,
2007). Beyond this classical PRC2 and/or PRC1 recruitment
model, evidence is emerging for a far more diverse and compli-
cated composition and recruitment process. Most notably, it
has become apparent that a plethora of distinct PRC1 com-
plexes exist, some of which contain RYBP instead of CBX (Ta-
vares et al., 2012). Furthermore, PRC1 can be present at
genomic loci in the absence of any PRC2 activity (Kahn et al.,
2016).hor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Notwithstanding our limited understanding of the complex
protein-protein and protein-DNA interactions in which the
PcG proteins are involved, it has become evident that PcG
proteins are important regulators of self-renewal and differen-
tiation of many types of pluripotent and adult stem cells
(Morey et al., 2013). Indeed, deregulation of their expression
or mutations in genes coding for PcG proteins can result
in cancer development (Herrera-Merchan et al., 2012). We
have previously shown that overexpression of the H3K27
methyltransferase Ezh2 in murine hematopoietic stem cells
prevents their exhaustion in serial transplantation experiments
(Kamminga et al., 2006). Furthermore, both EZH2 and BMI1
are important regulators of self-renewal of normal murine
and human hematopoietic stem cells (Rizo et al., 2008). Inter-
estingly, mutations in the EZH2 gene were later found in pa-
tients with myelodysplastic syndromes and acute myeloid
leukemia (Cancer Genome Atlas Research et al., 2013; Niko-
loski et al., 2010)
More recently, we showed that Cbx7, but not Cbx2, -4, or -8, is
a potent regulator of self-renewal of murine hematopoietic stem
cells, and its enforced overexpression resulted in increased self-
renewal and in phenotypically diverse leukemias (Klauke et al.,
2013). In human cells, systematic short-hairpin-mediated
repression of all CBX proteins in CD34+ cord blood cells resulted
in decreased proliferation and colony-forming unit ability. In this
experiment, knock down of CBX2 was shown to be most detri-
mental (van den Boom et al., 2013).
Collectively, these studies highlight the relevance of PcG pro-
teins, and particularly CBX proteins, in maintaining blood cell
homeostasis. As epigenetic changes are in principle reversible,
elucidating the function of epigenetic writers, readers, and
erasers in the context of healthy and malignant hematopoiesis
is indispensable for identifying novel therapeutic targets.
Therefore, in the current study, we asked to what extent
different CBX proteins are able to affect the balance between
self-renewal and production of mature blood cells of normal
human cord blood-derived primitive CD34+ hematopoietic
stem and progenitor cells. We identify CBX7 as a potent
inducer of self-renewal. Reversely, repression of CBX7 in
acute myeloid leukemia (AML) cells results in their terminal
differentiation. In addition, we identify evolutionary conserved
non-histone interaction partners of CBX7. These interaction
partners include multiple epigenetic enzymes, most notably
SETDB1, EHMT1, and EHMT2, which are all H3K9 methyl-
transferases that carry a potential lysine site for trimethyla-
tion. These sites are in a conserved peptide context, which
is similar to H3K9me3 and H3K27me3. Importantly, depletion
of SETDB1, similar to CBX7, also induced differentiation
of AML cells, suggesting that at least part of the self-renewal
potential of CBX7 is dependent on its interaction with an
H3K9 methyltransferase. H3K27me3 and H3K9me3 chro-
matin immunoprecipitation sequencing (ChIP-seq) and RNA
sequencing (RNA-seq) experiments revealed direct and
indirect CBX7 targets that comprise a complex network of
both classical histone modifications and epigenetic interac-
tions that collectively control the balance between self-
renewal and differentiation in primitive human hematopoietic
cells.RESULTS
CBX7 Enhances Self-Renewal of Human CD34+ Cord
Blood Cells In Vitro and In Vivo
To assess the role of the five different PRC1-CBX proteins on he-
matopoietic progenitor function, we overexpressed CBX2, 4, 6,
7, and 8 in CD34+ cord blood cells and performed colony-form-
ing unit (CFU) assays. Whereas overexpression of CBX7 and
CBX8 resulted in increased CFU frequencies, overexpression
of CBX2 and CBX4 resulted in lower CFU frequencies in compar-
ison to empty vector (EV) control. Overexpression of CBX6 had
no discernable effect (Figure S1A). Although CBX8 overexpres-
sion resulted in a slightly higher CFU frequency in comparison
to CBX7, replating of CBX7-overexpressing cells resulted in
higher CFU frequency (Figure S1B). Overexpression of CBX8
in CD34+ HSPCs showed no proliferative advantage in a cyto-
kine-driven suspension culture, whereas overexpression of
CBX7 resulted in a strong proliferative advantage and cells could
be kept in culture up to 10 weeks (Figure S1C). To determine the
role of the five different CBX proteins in regulating themore prim-
itive cell compartments, we performed cobblestone area-form-
ing cell (CAFC) assays. CBX7 overexpression increased the
CAFC day 35 frequency 10 fold, whereas CBX8 overexpres-
sion resulted in a small increase in CAFC frequency (Figure S1D).
In contrast, overexpression of CBX4 decreased the CAFC fre-
quency dramatically (50-fold), while overexpression of CBX2
and CBX6 had no effect. Reversely, short-hairpin-mediated
knock down of CBX7 in CD34+ HSPCs with two distinct short
hairpins resulted in a 3-fold reduced long-term culture initiating
cell (LTC-IC) frequency (Figure S1E).
These in vitro phenotypes prompted us to analyze endoge-
nous CBX expression levels in different primitive hematopoietic
cell subsets by using previously published microarray experi-
ments (Laurenti et al., 2013). CBX7 expression decreased dur-
ing differentiation from hematopoietic stem cells (HSC1 = Lin
CD34+CD38CD45RACD90+CD49f+, HSC2 = Lin CD34+
CD38CD45RACD90CD49f+) to more multipotent progenitor
(MPP), common myeloid progenitor (CMP), and guanosine
monophosphate (GMP) subsets (Figure S1F).
To assess consequences of CBX7 overexpression in in vivo,
we transplanted 23 105 CD34+GFP+ cells in sub-lethally irradi-
ated female NOD-SCID IL2rynull (NSG) mice. Mice transplanted
with CBX7-overexpressing cord blood cells showed significantly
higher engraftment of CD45+GFP+ cells in peripheral blood (PB)
(Figure 1A) and in bone marrow (BM) (Figure 1B).
To explore whether CBX7 overexpression would be able to
maintain human CD34+ HSPCs in a more primitive state for a
longer period ex vivo, we prolonged total in vitro culture time
from 3 to 7 days and transplanted 1.5 3 106 GFP+CD34+
HSPCs. Again, NSG mice transplanted with CBX7-overex-
pressing HSPCs displayed significantly higher engraftment in
PB (Figure 1C) and in bone marrow (Figure 1D). Mice trans-
planted with CBX7-overexpressing HSPCs showed a signifi-
cantly increased percentage of CD33+ cells in bone marrow,
suggesting that overexpression of CBX7 enhances myelopoi-
esis (Figures 1E and 1F). Similar results were obtained in the
PB after 18 weeks (data not shown). Furthermore, these
mice showed a significantly higher percentage of primitiveCell Reports 26, 1906–1918, February 12, 2019 1907
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Figure 1. CBX7 Overexpression Induces Enhanced Long-Term Engraftment, Myelopoiesis, and Self-Renewal of Primitive CD34+CD38
HSPCs In Vivo
(A) Human chimerism levels in the peripheral blood of NSGmice upon transplantation of 200,000 CD34+GFP+CBX7-overexpressing or empty vector (EV) control
cord blood cells.
(B) Primary recipients were sacrificed after 28–40 weeks, and human engraftment in bone marrow was evaluated.
(C) Human chimerism levels in the peripheral blood of NSG mice upon transplantation of 7 days ex vivo-cultured CBX7-overexpressing or empty vector control
CD34+ cord blood cells.
(D) Human engraftment in bone marrow of mice shown in (C), combined analysis of mice sacrificed after 18, 22, and 33 weeks post-transplant.
(E) Relative engraftment of humanCD19+, CD3+, and CD33+ cells within human CD45+GFP+ bonemarrow cells of mice shown in (C), combined analysis of mice
sacrificed after 18, 22, and 33 weeks post-transplantation.
(F) Human myeloid engraftment in bone marrow of mice shown in (C), combined analysis of mice sacrificed after 18, 22, and 33 weeks post-transplantation.
(G) Frequency of CD34+CD38 cells in huCD45+GFP+lin-CD34+ cells in bonemarrow of mice shown in (C), 18 combined analysis of mice sacrificed after 18, 22,
and 33 weeks post transplantation. Identically colored circles indicate 3 paired experimental and control samples that originate from the same cord. Statistical
analysis was performed using a two-tailed Mann-Whitney test.CD38 cells in the GFP+ LinCD34+ compartment (Figure 1G),
indicating that CBX7 controls in vivo proliferation or mainte-
nance of human HSPCs.
Genome-wide Transcriptional Consequences of CBX7
Overexpression in Human HSPCs
We next profiled the transcriptome of CBX7-overexpressing
CD34+ HSPCs by using RNA-seq. Differential expression anal-1908 Cell Reports 26, 1906–1918, February 12, 2019ysis showed a total of 1,463 genes significantly upregulated
and 1,183 genes significantly downregulated. (Tables S1 and
S2). To annotate CBX7-induced up- and downregulated
genes, we performed Gene Ontology (GO) enrichment analysis.
(Tables S3 and S4). This revealed that more than 100 genes
were associated with ‘‘cell differentiation,’’ particularly differen-
tiation of hematopoietic cells. (Figure 2A; Tables S3 and S4).
Furthermore, we found genes associated with cell cycle arrest
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Figure 2. RNA-Seq Analysis of CBX7-Overexpressing CD34+ HSPC
Sets of differentially expressed genes were screened for Gene Ontology (GO) enrichment. GO categories were enriched for ‘‘differentiation,’’ ‘‘cell cycle,’’
‘‘chromatin,’’ and ‘‘DNA,’’ shown using GO Chord plots. Preranked gene set enrichment analysis was performed for differentially expressed genes (FDR, <0.1)
upon overexpression of CBX7 in comparison to empty vector control cells.
(A) GO Chord plot of genes repressed upon overexpression of CBX7 in comparison to control cells, associated with the GO terms ‘‘differentiation’’ of various
hematopoietic cells.
(B and C) Gene Set Enrichment plot for genes downregulated upon overexpression of CBX7 reveal significant enrichment for (B) HSC genes and (C) NUP98-
HOXA9 target genes (p < 0.001).
(D) Heatmap containing genes upregulated upon overexpression of CBX7 and their expression in multiple normal hematopoietic subsets according to previously
published data from Laurenti et al., (2013).to be repressed. In contrast, upregulated genes revealed tran-
scripts related to ‘‘G1-S transition of mitotic cell cycle’’ (Fig-
ure S2A) and DNA replication (Figure S2B). These GO annota-tions are in good agreement with the in vitro and in vivo
observation that overexpression of CBX7 leads to elevated
self-renewal.Cell Reports 26, 1906–1918, February 12, 2019 1909
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Figure 3. Genetic or Pharmacological Inhibition of CBX7 Induces Differentiation in AML cells
(A) Short-hairpin-mediated knock down of CBX7mRNA (first panel, n = 5) in HL60 cells results in the loss of cell proliferation (second panel, n = 3), upregulation of
CD11b mRNA and protein (third and fourth panels, n = 5) after six days in culture. Multiple cells showed signs of differentiation upon knock down of CBX7 (5th
panel) (black = shCBX7#1, blue = shCBX7#2).
(B) Short-hairpin-mediated knock down of CBX7 mRNA (1st panel) in OCI-AML3 cells results in upregulation of CD14 mRNA (second panel) and protein (third
panel) after six days in culture (n = 2).
(C) Growth of OCI-AML3 cells treated with different concentrations of the CBX7 chromodomain inhibitor MS37452 after four days of culture (n = 3).
(D) Treatment of OCI-AML3 cells with MS37452 at a concentration of 10 mM results in increased expression of CD11b (n = 3).
(E) MS37452 induces monocyte and/or macrophage differentiation in OCI-AML3 cells. After treatment for 4 days with MS37452 at concentration of 10 mM,
cytospin preparations were stained with May-Gr€unwald Giemsa stain. Magnification, 403.
(legend continued on next page)
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Complementary, we performed Gene Set Enrichment Analysis
(GSEA) onapre-ranked list of differentially expressedgenes (false
discovery rate [FDR], <0.1). Interestingly, GSEA revealed a strong
negative correlation with a gene set containing genes with low
abundance in hematopoietic stem cells, indicating that increased
levels ofCBX7 result in repression of genes that are usually barely
expressed in hematopoietic stem cells (Figure 2B). Furthermore,
we identified two other sets with a high negative correlation,
both containing genes downregulated upon overexpression of
HOXA9eitherwithNUP98orMeis1, suggesting thatCBX7 targets
overlap with targets of these fusion oncogenes (Figure 2C; Fig-
ure S2C). Additionally, we found a strong negative correlation
with a gene set containing genes lower expressed in leukemic
stem cells (CD34+CD38) in comparison to leukemic blasts
(CD34+CD38+), suggesting that genes downregulated by CBX7
overexpression are indeed expressed lower in leukemic stem
cells than in leukemic blasts (Figure S2D).
To further characterize differentially expressed genes upon
CBX7 overexpression, we compared these with steady-state
transcriptomes of multiple subsets of hematopoietic cell types
by using a previously published expression dataset as a cross
reference (Laurenti et al., 2013). This analysis revealed that 378
transcripts that were higher expressed upon CBX7 overexpres-
sion were preferentially abundant in the more primitive cell com-
partments (HSC1, HSC2, and MPP versus multipotent lymphoid
progenitor [MLP], CMP, GMP, megakaryocyte erythroid progen-
itor [MEP], ETP-Thy, B-NKprec, and ProB) (Figure 2D; Table S5).
This suggests their involvement in maintaining elevated levels of
self-renewal upon overexpression of CBX7 in hematopoietic
stem cells.
CBX7 Expression Is Elevated in AML and Its Repression
Results in Differentiation of AML Cells
Our data show that CBX7 is able to increase self-renewal of
normal human hematopoietic stem and progenitor cells. To
explore a putative role for CBX7 in themaintenance of AML cells,
we first analyzed CBX7 mRNA expression levels in AML patient
samples in two previously published datasets. In the first data-
set, containing 529 AML patient samples from patients treated
at the Erasmus MC (Rotterdam, the Netherlands), CBX7 expres-
sion was significantly upregulated in comparison to peripheral-
blood-mobilized CD34+ cells (Verhaak et al., 2009). The highest
expression was observed in acute promyelocytic leukemia
(APL), leukemias with a normal karyotype and NPM1 mutated
leukemia (Figure S3A). We additionally analyzed data from the
Cancer Genome Atlas by Bloodspot (Bagger et al., 2016). Also,
in this patient cohort, CBX7 was significantly higher expressed
in multiple AML subtypes (Figure S3B).
To explore a functional role for high CBX7 expression in human
leukemia, we assessed to what extent depletion of CBX7 would
affect leukemic cell growth. As CBX7 is more abundantly ex-
pressed in APL (Figure S3A), we downregulated CBX7 mRNA
by using a short-hairpin approach in HL60 cells, which harbor(F) Primary AML cells, derived from 4 patients, were cultured on MS5 stromal cell
and cell proliferation was monitored. In 3 out of 4 patients, cell growth was stron
(G) Micrograph of primary AML cells of patient 2, co-cultured on MS5 stromal ce
(H) MS37452 dose-dependently induces expression of CD11 in primary AML cea t(15;17) translocation. Knock down of CBX7 was associated
with a reduced abundance of CBX7 mRNA to 40% of normal
levels (Figure 3A, first panel) and lower absolute cell numbers
after 6 days in culture (Figure 3A, second panel). Strikingly,
downregulation of CBX7 resulted in a significant increase of
CD11b expression, which is usually not expressed on primitive
APL-blasts but rather on mature monocytes, macrophages,
and granulocytes (Figure 3A, third panel). The changes of
CD11b protein levels were associated with an increased expres-
sion of CD11b on mRNA level (Figure 3A, fourth panel), and
morphological signs of cellular maturation upon May-Gr€unwald
Giemsa staining (Figure 3A, fifth panel).
It has been reported that CBX7 can interact with mutated
DNMT3A(R882) but not with wild-type DNMT3A in AML patient
samples (Koya et al., 2016). Therefore, we decided to downregu-
late CBX7 in OCI-AML3 cells, a cell line carrying DNMT3A R882
and mutant NPM1. Similar as in HL60 cells, upon knock down of
CBX7, OCI-AML3 cells started to differentiate and upregulated
the differentiation marker CD14 on the protein and mRNA level
(Figure 3B). In summary, these experiments indicate that CBX7
is necessary for maintaining leukemic cells in an undifferentiated
state, independent of DNMT3A.
We tested whether pharmacological inhibition of CBX7 would
result in similar effects as short-hairpin-mediated repression. To
this end, we cultured OCI-AML3 cells in the presence of
increasing concentrations of the small molecule MS37452,
which has been shown to bind to residues in the chromodomain
of CBX7, thereby preventing binding of CBX7 to proteins
harboring a trimethylated lysine residue. This loss of normal
chromodomain function resulted in derepression of PRC target
genes in prostate cancer cells (Ren et al., 2015). In OCI-AML3
cells, MS37452 resulted in the loss of cell growth in a time-
and dose-dependent manner (Figure 3C). Furthermore,
MS37452 treatment induced differentiation in leukemic cells,
as evidenced by upregulation of the differentiation marker
CD11b and by the strong increase of cells with a highly differen-
tiatedmorphology (Figure 3D and E).We observed similar effects
in THP1 cells, which carry a CDKN2A and RING1B deletion, sug-
gesting that the inhibitory effect of MS37452 is not due to dere-
pression of this locus (data not shown).
Finally, we tested whether pharmacological inhibition of CBX7
would similarly induce differentiation in primary, patient-derived,
leukemic cells. To this end, we initiated stroma-associated
cultures in which AML cells isolated from 4 different patients
were seeded on MS5 stromal cells. When cell growth was
observed, MS37452 was added to the cultures and cell growth
was evaluated. In 3 out of 4 patient samples, MS37452 potently
inhibited cell growth (Figure 3F). Figure 3G shows a micrograph
of these cultures, clearly indicating that overall cell growth is
severely impaired in the presence of the CBX7 inhibitor. In
the sample of patient 3, no clear inhibitory effect of MS37452
was observed. This seemingly non-responsive patient sam-
ple displayed particular cytogenetics (46,XX, del(7)(q22q36)).s. When primary cells started to grow, MS37452 was added to the co-cultures
gly inhibited by MS37452.
lls in the absence (left) of presence (right) of MS37452.
lls from patient 2, but not in refractory cells of patient 3.
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Figure 4. Mass Spectrometry Analysis Re-
veals Multiple H3K9 Methyltransferases as
CBX7-Binding Partners
(A) Search for putative interaction partners of CBX
proteins by label-freemass spectrometry. The plot
depicts CBX7 interaction partners ranked on the
basis of their cumulative rank score (derived from
the frequency of spectral counts, corrected for
GFP control samples), and the average abun-
dance of these proteins in the human PaxDB
database. The top-left corner represents priority
candidates. Red symbols indicate known tran-
scription factors, orange symbols refer to Poly-
comb proteins, and green symbols are proteins
with known lysine trimethylation sites.
(B) Peptide motif of the CBX7 interaction partners
harboring a lysine embedded in a motif highly
similar to H3K9me3 and H3K27me3.
(C) Duolink proximity ligation assay (PLA) of
endogenous SETDB1 and CBX7 interactions in
THP-1, OCI-AML3, and HL60 cells in the absence
(left panels) or presence of MS37452. Each PLA
signal (Cy3, red) is indicative of one detected
interaction event. Nuclei (blue) are stained with
40,6-diamidino-2-phenylindole (DAPI).Interestingly, EZH2 is located in this deleted region, suggesting
that canonical CBX7 target loci may not be recognized. However,
more samples would need to be tested to further provide insight
into the differential sensitivity of primary AML cells. In addition,
we determined the expression of the differentiation marker
CD11b on MS37452-exposed AML cells (Figure 3H) and found
increased CD11b expression of primary AML cells of patient 2
(responsive to MS37452) and no effect in patient 3 (non-respon-
sive toMS37452).Weobserved thatMS37452dose-dependently
resulted in increased expression of CD11b in primary AML cells
over time (Figure 3H). Collectively, these data show that at least
in some primary AML patient samples, inhibition of CBX7 has
potent anti-leukemic effects.
CBX7 Interacts with Trimethylated Non-Polycomb
Proteins
To further unravel the molecular mechanism by which CBX7 ex-
erts its potent activity, and taking into account that PcG proteins1912 Cell Reports 26, 1906–1918, February 12, 2019are known to operate in large protein
complexes, we decided to identify pro-
teins directly interacting with CBX.
We performed label-free mass spec-
trometry analysis of benzoase-treated
proteins that co-precipitated with FLAG-
tagged CBX7, FLAG-tagged CBX8, and
FLAG-tagged CBX4, using murine and
human cells. A protein fraction that co-
precipitated with FLAG-tagged GFP was
used as a negative control. To prioritize
candidates, we first removed proteins
with low spectral counts (<10% of the cu-
mulative spectral count) and then ranked
proteins in relation to their spectralcounts. We compared all mass spectrometry (MS) sets and
screened for consistent binding partners of both murine and hu-
man CBX proteins. As expected, multiple members of PRC1 and
PRC2 complexes were identified, including PCGF1, PCGF2,
PCGF5, PCGF6, SCML2, PHC1, PHC2, PHC3, BMI1, RING2,
RING1, EED, and SUZ12 (Figure 4A).
Because canonically CBX7 binds to the trimethylated lysine of
H3K27 through its chromodomain, we hypothesized that the
chromodomain could potentially associate with other trimethy-
lated lysines in non-histone proteins when they contain a peptide
context similar to H3K27. Therefore, we screened the list of
CBX7 human and murine binding partners for proteins harboring
a putative trimethylated lysine by using the PhosphoSitePlus
database (Hornbeck et al., 2015). This screen revealed a list of
218 human and murine trimethylated proteins, corresponding
to 335 known trimethylated human and murine peptides. We
only considered proteins with high spectral counts (top 15% of
the relative rank ordered proteins) and low protein abundance
(<100 ppm, https://pax-db.org/, average of all samples) and
corrected for the binding of each candidate to GFP. This strict
filtering narrowed our list down to four proteins (CDYL, SETDB1,
EHMT1, and EHMT2). We then applied the same filtering for mu-
rine Cbx7-binding proteins and identified SETDB1, EHMT1, and
EHMT2 as evolutionarily conserved binding partners. When us-
ing less strict filtering rules (top 70%) we also identified CDYL
as a binding partner of murine Cbx7. Interestingly, this list of
CBX7 interaction partners contains three H3K9 methyltrans-
ferases (EHMT1, EHMT2, and SETDB1) and one H3K9me3-
associated protein (CDYL). In our mass spectrometry data, we
were able to confirm the presence of EHMT1 and EHMT2 trime-
thylated peptides (Figures S4A and S4B). Next to our approach
to use spectral counts for identifying putative interaction part-
ners, we also calculated the relative enrichment in the exponen-
tially modified protein abundance index (emPAI) in the CBX7
sample over the control sample (FLAGGFP). All our candidate
proteins (SETDB1, EHMT1, EHMT2, and CDYL) showed a rela-
tive enrichment of at least 12. (Table S6).
We next assessed whether these human CBX7-binding part-
ners contain a common signature. Indeed, the consensus-
binding motif for CDYL, EHMT1, EHMT2, and SETDB1 was
found to be S[LT]PGHA.Kme3ST[PS], which is highly similar
to the peptide sequences to which human CBX7 is known to
bind: A[RILFYV]Kme3[ST] (Kaustov et al., 2011) (Figure 4B).
The similarity of these motifs suggests that CBX7 interacts
with these non-histone proteins via the chromodomain. Our
data show that human Polycomb CBX7 is able to interact
with multiple H3K9 methylation-associated proteins that har-
bor a lysine that can be trimethylated, and we chose to focus
on the CBX7-SETDB1 interaction. To validate the interaction of
SETDB1 and CBX7 in FLAG-tagged CBX7-overexpressing
K562 cells, we stained the immunoblots for CBX7 and SETDB1
(Figure S4C).
In addition, we performed proximity ligation assays (PLA) of
endogenous SETDB1 and CBX7 in 3 different human acute
myeloid and lymphoid cell lines (HL60, THP1, and OCI-AML3)
to confirm that CBX7 and SETDB1 are indeed bona fide binding
partners and found intense co-staining throughout the nucleus
(Figure 4C, left panels). We next determined whether blocking
the chromodomain of CBX7 by using MS37452 would result in
loss of these CBX7-SETDB1 interactions. Indeed, MS37452
dose-dependently inhibited this interaction, as revealed by
PLA analyses in the all leukemic cell lines (Figure 4C).
These data suggest that the chromobox of CBX7, which is
essential and sufficient to bind lysine-trimethylated residues, is
required for physiological binding to SETDB1. We identify a
non-canonical (non-H3K27me3) role for CBX7 in crosstalking
to epigenetic pathways governing H3K9 methylation.
Identification of CBX7 Target Loci and Their Association
with H3K9me3 and H3K27me3
To identify genes directly controlled by CBX7 and to unravel their
association with H3K27me3 and H3K9me3, we performed ChIP-
seq experiments in primary HSPCs from different cord blood do-
nors overexpressing either CBX7 or an empty vector. Before
deep sequencing we tested each sample for enrichment at
known target loci by qPCR (Figure 5A). Following sequencing,
we only considered peaks that were present in at least two outof three independent ChIP-seq samples with an adjusted p
value < 0.05. Upon overexpression, CBX7 peaks were strongly
enriched at the transcription start site (TSS), confirming that
CBX7 acted preferentially at core promoter regions. (Figure 5B).
We next searched genome wide for loci that were targeted by
CBX7 and marked by H3K9me3 or H3K27me3. We observed
that 23% of all CBX7 peaks were overlapping with H3K9me3,
whereas 44% were overlapping with H3K27me3. Furthermore,
13% of all CBX7 peaks were associated with both H3K9me3
and H3K27me3 (Figure 5C), culminating in 1/3 of all CBX7
peaks being associated with H3K9me3 (p < 1.74e244).
Interestingly, in CBX7-overexpressing CD34+ cells 20% of
all TSSs marked with CBX7 were also marked with H3K9me3,
providing further evidence of a joint gene regulatory function
(Figure S5A). These molecular patterns are compatible with a
model in which H3K9methyltransferases act as binding partners
of CBX7, at least for a subset of the genomic sites bound by
CBX7.
To refine the list of direct targets of CBX7, we performed an
integrative analysis of RNA-seq and ChIP-seq data and
searched for genes repressed upon overexpression of CBX7,
which were additionally marked by CBX7. Out of 1,183
repressed genes, 220 showed CBX7 peaks within 5 kb around
their TSS and an additional 63 genes were marked within the
gene body (Figure S5B shows some illustrative examples). All
these 283 genes are likely to be primary targets of CBX7 in hu-
man HSPCs (Table S7).
The large majority of these primary targets (246 out of the 283)
were also marked by H3K27me3 within 5 kb around the gene
body, confirming the well-known interaction of CBXwith the Pol-
ycomb repressive mark set by EZH2. Interestingly, and in agree-
ment with our finding that CBX7 directly interacts with various
H3K9 methyltranferases, 178 (i.e., 62%) of these direct CBX7
targets were also marked with H3K9me3 (Figure 5D).
Collectively, these molecular signatures reveal functional non-
canonical cross talk between Polycomb CBX proteins and H3K9
methylation, as first suggested by the physical interaction of
CBX7 and SETDB1, EHMT1, and EHMT2.
SETDB1 and CBX7 Share Functional Activity in AML
Cells
As we identified the H3K9 methyltransferase SETDB1 as a
CBX7-interacting protein and as we found that approximately
one-third of the CBX7 genomic target loci were also covered
by H3K9me3, we evaluated the function of SETDB1 in leukemic
cells. Mutations in SETDB1 are associated with the develop-
ment of clonal hematopoiesis and SETDB1 is higher expressed
in leukemic stem cells compared to leukemic blasts in AML pa-
tient samples (Eppert et al., 2011; Steensma et al., 2015); there-
fore, we set out to investigate whether short hairpin RNA
(shRNA)-mediated knock down of SETDB1 in myeloid leukemic
cells would phenocopy the effects observed upon CBX7 repres-
sion. We observed a loss of LTC-IC potential of normal CD34+
cells upon SETDB1 repression (data not shown). Similarly,
SETDB1 knock down strongly impaired proliferation of HL60
cells (Figure 6A). In addition, SETDB1 knock down resulted in
increased expression of CD11b, similar as CBX7 in HL60 cells
(Figure 6B). Knock down of SETDB1 resulted in increasedCell Reports 26, 1906–1918, February 12, 2019 1913
DCB
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Figure 5. Identification of CBX7 Genome-wide Binding Sites in Primary Human CD34+ Cells and Their Association with H3K9me3 and
H3K27me3
(A) ChIP-qPCR validation of selected positive and negative H3K9me3, H3K27me3, and CBX7 target loci, and IgG (control). (Data from one (out of 3) representative
experiment are shown).
(B) Genome-wide distribution of H3K9me3, H3K27me3, and CBX7 peaks to nearest TSS in base pairs (bps).
(C) Pie chart showing absolute and relative numbers of genome-wide CBX7 peaks and their overlap with H3K9me3 and/or H3K27me3 peaks.
(D) Venn diagram showing overlap of genes marked with H3K27me3 (CBX7 H3K27me3) and H3K9me3 (CBX7 H3K9me3) in CBX7-overexpressing CD34+
HSPCs, H3K9me3 in control CD34+ HSPCs (empty vector H3K9me3) and direct targets of CBX7.expression of CBX7 (Figure 6C). Also, similar to CBX7, knock
down of SETDB1 in OCI-AML3 cells induced increased the
expression of differentiation markers (Figures 6D and 6E) and
reduced proliferation (Figure 6F). Finally, the repression of
SETDB1 resulted in the appearance of CD14+ cells 6 days after
culturing (Figure 6G). The CD14 locus is a direct CBX7 target, as1914 Cell Reports 26, 1906–1918, February 12, 2019in primary CD34+ cells CD14 is in the top three downregulated
genes upon overexpression of CBX7 and is marked with
CBX7, H3K27me3, and H3K9me3 (Figure S4B). These experi-
mental data indicate that CBX7 and SETDB1 jointly repress
genes that are important for differentiation of leukemic cells to-
ward mature myeloid cells.
ED
GF
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BA Figure 6. Repression of SETDB1 Pheno-
copies Repression of CBX7 in Leukemic
Cells
(A) Absolute cell numbers after 6 days of culturing
150,000 HL60 cells upon short-hairpin-mediated
knock down of SETDB1 (n = 3).
(B) Percentage of CD11b+ HL60 cells after 9 days
in culture upon knock down of SETDB1 (n = 2).
(C) Fold change of CBX7 mRNA (left) and hu-
SETDB1 mRNA (right) expression in OCI-AML3
cells 24 h after transduction with multiple short
hairpins targeting CBX7 or SETDB1 (n = 5).
(D and E) Fold change of CD11b (D) and CD14 (E)
mRNA expression in OCI-AML3 cells 24 h after
transduction with multiple short hairpins targeting
CBX7 or SETDB1 (n = 3–5).
(F) Absolute cell numbers after 6 days of culturing
150,000 OCI-AML3 cells upon short-hairpin-
mediated knock down of SETDB1 or CBX7 (n = 4).
(G) Percentage of CD14+ cells (left) and fold
change of CD14 mRNA expression (right) upon
knock down of SETDB1 in OCI-AML3 cells six
days after sort (n = 4). All statistical analyses were
performed using paired t test, two-tailed.DISCUSSION
In this study, we identify CBX7 as a regulator of self-renewal
in normal and leukemic hematopoietic cells. We describe the
complex molecular architecture of CBX7-induced cell prolifera-Cell Reportion and discover a biologically relevant,
non-canonical role for CBX7 as a binding
partner of multiple H3K9 methyltrans-
ferases, including SETDB1. Because
transplantation of CBX7-overexpressing
CD34+ cells resulted in an increased
frequency of myeloid CD33+ cells and
primitive CD34+CD38- cells in the bone
marrow and CBX7 overexpression re-
sulted in repression of differentiation-
associated genes, we explored the role
of CBX7 in AML. We show that genetic
repression and pharmacological inhibi-
tion of CBX7 in AML cells impairs their
proliferation and results in derepression
of differentiation-associated genes.
Polycomb CBX proteins are key com-
ponentsof thePRC1complex,where their
function is believed to be essential for the
recruitment of PRC1 to H3K27me3-modi-
fied genomic loci. Thus, the chromobox
domain contained in all CBX proteins is
able to recognize H3K27me3 modifica-
tions deposited by EZH1 and/or EZH2 as
part of the PRC2 complex, which contrib-
utes to the repression of target genes.
Whereas theDrosophila genome contains
a single cbx gene, during evolution ampli-
fication of CBX homologs has occurred inmammals. CBX2,4,6,7, and8 have all been described to
be part of the PRC1 complex, and it is likely that various assem-
blies of PRC1 have distinct biological targets. In this project, we
investigated the role of all five PRC1-CBX proteins in regulating
human CD34+ HSPCs. We show that CBX7 is uniquely able tots 26, 1906–1918, February 12, 2019 1915
enhance cell growth of primitive hematopoietic cell subsets.
Additionally, transplantation of CBX7-overexpressing CD34+
cells resulted in enhanced long-term engraftment, multi-lineage
differentiation potential, and an increased frequency of myeloid
CD33+ cells and primitive CD34+CD38 cells in the bone
marrow. These results are reminiscent of data of mouse Cbx7,
which we reported earlier (Klauke et al., 2013) and established
CBX7 as an important evolutionary conserved regulator of self-
renewal of human CD34+ HSPCs.
Overexpression of CBX7 resulted in the repression of genes
associatedwith differentiation and led to an upregulation of genes
involved in cell cycle and DNA replication. ChIP-seq analysis
showed that 1/3 of the repressed differentiation-associated
geneswere direct CBX7 targets. Furthermore,manygenes,which
wereupregulateduponoverexpressionofCBX7, arepreferentially
expressed by primitive hematopoietic cell subsets, and, thus, are
likely to contribute to themaintenance of the primitive phenotype.
Our data indicate that CBX7 regulates the self-renewal activity
of primitive cells. As we show that CBX7 represses genes impor-
tant for differentiation, we hypothesized that CBX7may also play
a role in AML, where self-renewal is enhanced and, conversely,
differentiation is repressed. We show that knock down of
CBX7 in leukemic cell lines and primary patient samples affects
their proliferation and results in derepression of genes that are
normally expressed on differentiated cells.
The molecular mechanism by which CBX7 represses differen-
tiation-inducing genes remains to be elucidated, but our studies
strongly suggest that the interplay between the canonical,
H3K27me3-mediated, and a non-canonical, H3K9-mediated
pathway plays an important role. Whereas in vitro the Drosophila
Polycomb Cbx protein can only recognize H3K27me3 but not
H3K9me3, biochemical studies have revealed that multiple
mammalian CBX homologs can also bind to H3K9me3 in cell-
free systems, each with different binding affinities (Bernstein
et al., 2006; Kaustov et al., 2011). So far, no H3K9 methyltrans-
ferases were described to interact with CBX proteins in vivo.
As CBX proteins interact with trimethylated lysine residues on
histone proteins via their chromodomain, we hypothesized that
CBX proteins might also interact with non-histone proteins
harboring a trimethylated lysine embedded in a motif highly
similar to histone proteins. Indeed, mass spectrometry analysis
revealedmultiple of such candidates. Interestingly, all four evolu-
tionarily conserved CBX interacting proteins (EHMT1 [also
known as GLP], EHMT2 [also known as G9A], SETDB1, and
CDYL) have been shown to physically interact and are strongly
associated with H3K9 methylation (Fritsch et al., 2010).
We focused our further studies on the interaction between
CBX7 and SETDB1. SETDB1 is an H3K9 methyltransferase
that is best known for its role in repressing the expression of
endogenous retroviral elements in the genome (Collins et al.,
2015). Interestingly, both SETDB1 and CBX7 have been identi-
fied as regulators of embryonic stem cell states (Bilodeau
et al., 2009), but the role of SETDB1 in hematopoiesis has only
recently emerged. Interestingly, mutations in SETDB1 have
been associated with clonal hematopoiesis in elderly individuals
(Steensma et al., 2015). Recently, it has been shown that deletion
of Setdb1 in murine hematopoietic stem cells results in bone
marrow failure (Koide et al., 2016).1916 Cell Reports 26, 1906–1918, February 12, 2019Biochemical studies have revealed that the chromodomain of
CBX7 has high affinity for a trimethylated 24-amino acid peptide,
representing exactly the consensus amino acid sequence of
SETDB1 (amino acids 1,157 to 1,181). In fact, the affinity of
CBX7 for this sequence is higher for peptides representing the
amino acid sequence of H3K27me3 or H3K9me3 (Kaustov
et al., 2011). Three lysine residues of SETDB1 have been identi-
fied that can be trimethylated (K490, K1170, and K1178), and all
could serve as putative binding sites for CBX7 (Hornbeck et al.,
2015).
In accordancewith the direct in vivo interaction betweenCBX7
and SETDB1, nearly one-third of all CBX7 target loci were simul-
taneously covered with H3K9me3. In addition, the fact that 62
out of the 95 differentially expressed direct CBX7 target genes
associated with differentiation were marked by both CBX7 and
H3K9me3, strongly suggesting that self-renewal of human
HSPCs is dependent on CBX7-mediated joint repression of
target loci by methylation of both H3K27 and H3K9.
Reversely, we demonstrate that proliferation is decreased in
leukemic cells when either CBX7 or SETDB1 is downregulated
or when CBX7 is pharmacologically inhibited. Similarly, it has
been shown that exposure of murine AML blasts to the EHMT2
inhibitor UNC0638 leads to inhibition of growth and induction
of myeloid differentiation (Lehnertz et al., 2014).
As for the exact molecular mechanism by which CBX7,
SETDB1, and H3K9me3 interact, we hypothesize that such inter-
actions are locus specific and dependent on the composition of
the protein complex involved. We speculate that regulation
follows a stepwise program, where trimethylated SETDB1
initially converts H3K9me or H3K9me2 into H3K9me3, resulting
in attraction of PRC1 by binding of CBX7 to SETDB1. An alterna-
tive, not mutually exclusive, possibility is that CBX7 first recog-
nizes trimethylated SETDB1, by which it is then recruited to
H3K9me2 loci to ensure further chromatin compaction. These
recruitment models would be independent of H3K27me3/
PRC2. At loci where both H3K27me3 and H3K9me3 histone
marks are present, CBX7 could be recruited to both. It is inter-
esting to note that one of the CBX7-binding proteins we identi-
fied, CDYL, can bind to EZH2 as well as to SETDB1 (Esca-
milla-Del-Arenal et al., 2013; Fritsch et al., 2010; Zhang et al.,
2011), allowing for multiple alternative Polycomb and H3K9
methyltransferase interactions. At this point, we do not formally
know whether trimethylation of SETDB1 (and EHMT1 and
EHMT2) in leukemic cells is required for recognition by CBX7,
and if so, how trimethylation of these H3K9 methyltransferases
is regulated. Further elucidation of the daunting complexities
by which seemingly independent epigenetic pathways converge
will allow the understanding of themolecular machinery bywhich
self-renewal is ensured. Disruption of these self-renewal path-
ways is likely to offer therapeutic opportunities in leukemia.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Human BD Fc block BD Bioscience 564220
CD16/ CD32 Mouse BD Fc block BD Bioscience 553142
Mouse anti human CD3 APC-Cy7 (SK7) BD Bioscience 557832
Mouse anti human CD4 PE-Cy7 (SK3) BD Bioscience 557852
Mouse anti human CD33 BV421(WM53) BD Bioscience 562854
Mouse anti human CD45 APC (HI30) BD Bioscience 560973
Mouse anti human CD19 PE (HIB19) BD Bioscience 555413
BD Horizon Brilliant Stain buffer BD Bioscience 563794
Mouse anti human CD38 PE (HIT2) BD Bioscience 555460
Mouse anti human CD90 AF700 (5E10) BioLegend 328120
Mouse anti human CD34 APC (581) BD Bioscience 555824
Mouse anti human CD45 RA PE-Cy7 (L48) BD Bioscience 337186
Mouse anti human CD45 BV421 (HI30) BioLegend 304032
Mouse anti human CD2 PE-Cy5 (RPA-2.10) BioLegend 300210
Mouse anti human CD3 PE-Cy5 (UCHTI) BioLegend 300410
Mouse anti human CD4 PE-Cy5 (RPA-T4) BioLegend 300510
Mouse anti human CD7 PE-Cy5 (6B7) BioLegend 343110
Mouse anti human CD8 PE-Cy5 (RPA-T8) BioLegend 301010
Mouse anti human CD19 PE-Cy5 (HIB19) BioLegend 302210
Mouse anti human CD20 PE-Cy5 (2H7) BioLegend 302308
Mouse anti human CD235a PE-Cy5 (HIR2) BioLegend 306606
Mouse anti human CD11b PE-Cy5 (ICRF44) BioLegend 301308
Mouse anti human CD14 PE-Cy5 (TuK4), TRI-COLOR ThermoFisher Scientific MHCD1406
Mouse anti human CD56 PE-Cy5 (MEM-188) BioLegend 304608
Mouse Anti-Human Alexa Fluor 700 CD14 Clone
M5E2 (RUO)
BD Bioscience 557923
Mouse Anti-Human BV421 CD11b/MAC-1 (RUO) BD Bioscience 562632
Human anti CD34 PE-Cy7 (8G12) BD Bioscience 348811
H3K9me3 polyclonal antibody- Premium Diagenode C15410193
Anti H3K27me3 Merck 07-449
Anti CBX7 Merck 07-981
Pierce Protein A/G Magnetic beads Thermo Scientific #88803
Monoclonal ANTI-FLAG M2 antibody Sigma F3165-2 mg
Polyclonal rabbit anti human/mouse CBX7 p15 Santa Cruz Biotechnology SC 70-232
SETDB1 Antibody (5H6A12) Pierce Protein MA5-15722
Biological Samples
Human Cord blood sampes Department Obstetrics, Isala Hospital
Zwolle
N/A
Primary AML samples Department of Hematology, UMCG N/A
Chemicals, Peptides, and Recombinant Proteins
IMDM 2% FCS StemCell Technologies # 07700
MethoCult H4435 Enriched StemCell Technologies #04435 and 04445
Myelocult H5100 StemCell Technologies #05100 and 05150
StemSpan SFEM StemCell Technologies # 09650
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Hydrocortisone StemCell Technologies #07904
Human recombinant TPO RnD 288-TP-200
Human recombinant FLT3L RnD 308-FK-025
Human recombinant SCF RnD 255-SC-050
Human recombinant IL3 Sigma I1646
Mouse recombinant IL3 RnDSystems 403-ml-50
RetroNectin 2,5 mg Westburg/ Takara T100/B
Hexadimethrine bromide Sigma h-9268
FuGene HD transfection reagent Promega E2312
Formaldehyde, 37% formaldehyde solution Santa Cruz Biotechnology Sc-203049
SDS Solution, 20% Fisher Scientific BP 1311-1
cOmplete, EDTA-free Protease Inhibitor Cocktail Merck #000000011873580001
QIAquick PCR Purification Kit Quiagen #28104
Novagen Benzoase Nuclease, Purity 99% Merck Millipore 70664
SnakeSkin Dialysis Tubing, 7K MWCO, 22mm Thermo Scientific 68700
3xFlag peptide Sigma F3290-4MG
CryoStor CS10 StemCell Technologies #07930
Protease Inhibitor Cocktail Sigma P8340
Anti-Flag M2 Magnetic beads Sigma M8823
NT Protein Labeling kit Red-NHS Nanotemper MO-L001
MS37452 Sigma SML1405
Deposited Data
RNA Seq data This paper https://www.ebi.ac.uk/ena/data/
view/PRJEB22831
ChIP Seq data This paper https://www.ebi.ac.uk/ena/data/
view/PRJEB22344
Experimental Models: Cell Lines
MS5 cells DSMZ ACC 441
HL60 cells ATCC DSMZ CCL-240 ACC 3
OCI-AML3 cells DSMZ ACC 582
32D cells Kind gift from Ivo Touw
PG13 cells ATCC CRL-10686
Phoenix-ECO cells ATCC CRL-3214
K562 cells ATCC CCL-243
293FT ThermoFisher Scientific R70007
Experimental Models: Organisms/Strains
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ Mice were purchased from Charles
River Laboratory (L’Arbesle Cedex,
France) and bred in house.
N/A
Oligonucleotides
See Table S8 N/A
Software and Algorithms
Graphpad Prism (v5-7) Graphpad Prism https://www.graphpad.com
ELDA (Hu and Smyth, 2009) http://bioinf.wehi.edu.au/software/elda/
FlowJo Version X.0.7
Other
CD34+ MicrobeadKit Miltenyi Biotec 130-056-702
Lymphoprep Stem cell technologies 7861
LS Columns Miltenyi Biotec 130-042-401
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gerald de
Haan (g.de.haan@umcg.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Mouse experiments were performed in line with international and national guidelines. All experiments were approved by the Institu-
tional Animal Care and Use Committee of the University of Groningen (IACUC-RUG).
For all xenotransplantation studies, we performed single cord transplantations of freshly isolated CD34+ cord blood cells. Female
11-22 weeks old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were radiated three hours before transplantation with 1.8 Gy. In each
experiment age of mice was balanced with maximum 2 weeks of difference between the experimental and control group. No anti-
biotic prophylaxis after radiation was given.
Human cord blood samples
CD34+ cord blood isolation
Cord blood was obtained from healthy full-term pregnancies after informed consent in accordance with the Declaration of Helsinki
from the Obstetrics Department at the Isala Hospital in Zwolle, the Netherlands. Initially, cord blood volume and cell counts were
measured and then diluted 1:1 with PBS+ 2mM EDTA+0.5% BSA. Maximum 30 mL of diluted cord blood was carefully layered
on 15 mL of Lymphoprep in a 50ml falcon tube and centrifuged for 20 minutes, 800 g, without brakes. Middle layer containing mono-
nuclear cells was harvested and diluted 1:1 with PBS 2mM EDTA 0.5% BSA and then centrifuged for 5 minutes at 800 g. Cell pellets
were collected and washed with PBS 2mM EDTA 0.5% BSA and centrifuged for 10 minutes at 200 g. Immunomagnetic labeling and
separation were performed according to the manufacturer’s manual of the CD34 MicroBead Kit, human (Miltenyi Biotec). Cells were
either used immediately for experiments or frozen in Cryostor CS10.
Cell lines
Phoenix-ECO cells were culture in DMEM +1% P/S + 10% heat-inactivated FCS. PG13 cells were culture in DMEM +1% P/S + 10%
heat-inactivated FCS. HEK293FT cells were culture in DMEM +1% P/S + 10% heat-inactivated FCS. HL60 cells were cultured in
RPMI+1%P/S+20% heat-inactivated FCS. OCI-AML3 cells were cultured in RPMI+1%P/S+10% heat-inactivated FCS. K562 cells
were cultured in RPMI+1%P/S+10% heat-inactivated FCS.
Primary leukemic cells
Primary AML cells were provided by dr. JJ Schuringa from the Department of Hematology, University Medical Center Groningen after
informed consent.
METHOD DETAILS
Cloning of retroviral vector constructs
The consensus cDNA of CBX2,4,6,7 and 8 and FLAG-tagged versions of the cDNA were inserted in the retroviral vector backbone of
SF91-IRES-GFP (Klauke et al., 2013) upstream of IRES by PCR based cloning using Not1 and Sal1 restriction sites. Primers used for
PCR based cloning are listed above. FLAG-tagged GFP vector was cloned by vector-PCR of SF91-FLAG tagged muCbx7 (Klauke
et al., 2013) with MluI restriction site containing primers and subsequent ligation.
Cloning of flag-tagged huSETDB1 cDNA in pRRLA
A FLAG-tagged versions of SETDB1 cDNA was inserted in the lentiviral vector backbone of pRRLA IRES-GFP upstream of IRES by
PCR based cloning using Mlu1 and Xba1 restriction sites. Primers used for PCR based cloning are listed above.
Cloning of short-hairpins in lentiviral expression vectors
Corresponding oligos for SCR, shCBX7, shSETDB1#3 and shSETDB1#4were annealed and cloned into the empty pLKO.1_mCherry
vector upon digestion with Age1 and EcoR1.
Transduction of 32D cells
Initially, 300,000 Phoenix-ECO cells/well (of a six-well plate) were seeded in DMEM+1%P/S+10%FCS. On day 2 cells were
transfected with 1 mg of plasmid with the help of FuGene in a 1:3 ratio. 24 hours after transfection medium was changed to
RPMI+10%FCS+1%P/S. On day 4 non-treated six- well plates were coated with RetroNectin according to the manufacturer’s
manual. Viral supernatant was harvested and filtered through a sterile syringe filter with a 0.45 mm pore size hydrophilic PVDF
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added/well. Six-well plates were centrifuged for 45 minutes at room temperature for 45 minutes at 400 G. 24 hours after transduction
virus-supernatant was replaced by RPMI+10%FCS+1%P/S+ muIL3 (10 ng/ml).
Production of a stable retroviral producer cell line (PG13)
Initially, 300,000 Phoenix-ECO cells/well (of a six-well plate) were seeded in DMEM+1%P/S+10%FCS. On day 2 cells were trans-
fected with 1 mg of plasmid with the help of FuGene in a 1:3 ratio. 24 hours after transfection medium was refreshed and 10,000
PG13 cells were plated out/ well in a tissue culture treated six-well plate. 48 hours after transfection viral supernatant was harvested
and used to transduce the retroviral packaging cell line PG13 with the help of Hexadimethrine bromide (2 mg/ml). One day after
transduction medium of transduced PG13 was changed to DMEM+1%P/S+10%FCS and cultured at 37C/5% CO2.
Production of lentiviral supernatant
2.75 106 293FT cells were plated in gelatin coated cell-culture treated 10 cmdishes in DMEM+10%FCS+1%P/S and incubated over-
night at 37C/5%CO2. On the next day cells were transfectedwith 3 mg of the pLKO.1 or pRRLA vector, 3 mg of the packaging plasmid
pCMV8.91 and 0.7 mg of envelope plasmid VSV-G and 21 ml of FuGene. On the next day medium was changed to either StemSpan
SFEM or RPMI. Two days after transfection the virus was collected, filtered through a sterile syringe filter with a 0.45 mm pore size
hydrophilic PVDF membrane and used either immediately for transduction or was frozen.
Retroviral virus production and transduction of CD34+ cells
24 hours before the first transduction round CD34+ cells were prestimulated in StemSpan SFEM with SCF 100 ng/ml, FLT3L
100 ng/ml and TPO 100 ng/ml at 37C and 5% CO2. Medium of transduced PG13 cells was changed to StemSpan SFEM. On
the day of transduction not tissue-cultured six-well plates were coated with RetroNectin according to the manufacturer’s manual.
Then viral supernatant of virus-producing PG13 cells was harvested and filtered through a sterile syringe filter with a 0.45 mm pore
size hydrophilic PVDFmembrane. Between 500,000 and 1,000,000 CD34+ cells were transducedwith 2mL of viral supernatant in the
presence of SCF 100 ng/ml, FLT3L 100 ng/ml, TPO 100 ng/ml and Hexadimethrine bromide to a final concentration of 2 mg/ml.
Six-well plates were centrifuged at 400 g for 1 hour at room temperature. Transduction was repeated two times in 8-12 hour time
intervals. After last transduction round medium was changed to StemSpan SFEM with SCF 100 ng/ml, FLT3L 100 ng/ml and TPO
100 ng/ml.
Lentiviral transduction of CD34+ cells
CD34+ cells were cultured in StemSpan SFEM with SCF 100 ng/ml, FLT3L 100 ng/ml and TPO 100 ng/ml 24 hours before first
transduction round at 37C and 5%CO2. On the day of transduction not tissue-cultured six-well plates were coated with RetroNectin
according to themanufacturer’s manual. Lentiviral supernatant was thawn on ice. Between 500,000 and 1,000,000 CD34+ cells were
transduced with 2 mL of viral supernatant in the presence of SCF 100 ng/ml, FLT3L 100 ng/ml, TPO 100 ng/ml and Hexadimethrine
bromide 2 mg/ml. Six-well plates were centrifuged at 400G for 1 hour at room temperature. Transduction was repeated once in 8-12
hour time intervals. After last transduction round medium was changed back to StemSpan SFEM containing SCF 100 ng/ml, FLT3L
100 ng/ml and TPO 100 ng/ml.
Lentiviral transduction of HL60 and OCI-AML3 cells
On the day of transduction not tissue-cultured six-well plates were coated with RetroNectin according to themanufacturer’s manual.
Between 300,000 and 500,000 cells were transduced in 2 mL of viral supernatant containing Hexadimethrine bromide 2 mg/ml.
Six-well plates were centrifuged at 400G for 1 hour at room temperature. Transduction was repeated once in 8-12 hour time intervals.
After last transduction round medium was changed back to RPMI+1%P/S+10% (OCI-AML3) or 20% of FCS (HL60). At several time
points cells were counted manually with a hemacytometer.
MS37452 treatment of OCI-AML3 cells
Initially, 500.000 OCI-AML3 cells/well (of a six-well plate) were seeded in RPMI+1%P/S+10% heat-inactivated FCS supplemented
with MS37452 (dissolved in DMSO at a concentration of 50mM) at different concentrations. After four days cells were counted manu-
ally using a hemacytometer.
FACS analysis of HL60 and OCI-AML3 cells
Samples were incubated with Human BD Fc block to prevent unspecific binding at 4C in the dark. After blocking, 5 ml mouse
anti huCD11b BV421 and/or 5 ml mouse anti huCD14 Alexa Fluor 700 antibodies were added and samples were incubated for
20-25 minutes at 4C in the dark. Afterward, cells were washed and resuspended with PBS+BSA 0.2% containing a viability dye
(PI). Samples were analyzed on a BD FACSCanto II.
Sort of GFP+CD34+ cells (MoFlo Astrios and MoFloXDP)
24 hours after the last transduction round cells were harvested, washed and resuspended in PBS+BSA 0.2%. Cells were incubated
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mouse anti huCD34 PE-Cy7 was added and incubated at 4 degrees for 20 minutes. Cells were washed with PBS+BSA 0.2% and
resuspended in PBS+BSA 0.2% with the viability dye (PI).
CFU assay
All experiments with CD34+ cells were performed with single (not pooled) cords (except Chip-Seq experiments). 5,000 CD34+GFP+
cells were sorted in a FACS tube containing 1 mL of IMDM 2% FBS. 0.3 mL of the sorted cells in IMDM 2%FCS were added to a pre-
aliquoted 3 mL MethoCult tube. Afterward the tube was vortexed for at least 4 s and then let stand for a minimum of 5 minutes. For
dispensing the MethoCult mixture into 35 mm culture dishes a 3 mL syringe with a 16 gauge Blunt-End Needle was used to add
1.1 mL per dish. Dishes were cultured at 37C / 5% CO2 conditions. Colonies were counted and typed after 14 days. For replating
cells fromprimary disheswere harvested, centrifuged and countedwith a hemocytometer. For CBX7 5,000 cells and for CBX8 30,000
cells were plated out as described above. Control cells were plated out at same cell numbers as experimental groups. Figure 1 A+B
show single data points of each experiment. Each single experiment was performed in duplicates and the average of the technical
replicates was plotted.
Cobblestone area-forming cell assay
96-well flat-bottom plates were pre-coated with 0.1% gelatin. Two days before sort 10,000 MS5 cells were plated in 200 ml of Mye-
locult H5100 supplemented with 106 M hydrocortisone +1% P/S. On the next day cells were radiated with 30 Gy. One day post
radiation CD34+GFP+ cells were sorted directly into 96-well plates at limiting dilution and cultured for 5 weekswith weekly performed
half-medium changes. Cobblestones were analyzed with a phase-contrast microscope. Frequency of each experiment was calcu-
lated with ELDA software. (Hu and Smyth, 2009) Figure 1D shows single data points of each experiment. (The y axis indicates the
number of cells that need to be plated for a CAFC to develop.)
Long-term culture initiating cell assay
96-well flat-bottom plates were pre-coated with 0.1% gelatin. Two days before sort 10,000 MS5 cells were plated out in 200 ml of
Myelocult H5100 supplemented with 106 M hydrocortisone.
Cells were sorted directly into 96-well plates at limiting dilution and cultured for 5 weeks with weekly performed half-medium
changes. After 5 weeks medium was replaced by Methocult H4335 and incubated for two further weeks at 37C/5% CO2.
Colony-formation was accessed by phase-contrast microscopy. Frequency of each experiment was calculated with ELDA software.
(The y axis indicates the number of cells that need to be plated for a LTC-IC to develop)
Suspension culture experiment with CBX7, CBX8 and empty vector overexpressing cells
100,000 CD34+GFP+ cells were sorted in a six-well plate containing 2 mL of Myelocult H5100, 1% P/S, 106 M hydrocortisone, TPO
100 ng/ml, IL3 50 ng/ml, SCF 100 ng/ml, FLT3L 100 ng/ml. Cells were cultured at 37C/5%CO2. Cells were counted manually with a
hemacytometer every week and 100,000 cells were re-seeded under the same conditions.
Xenotransplantation of transduced CD34+ cells 24 hours after last transduction round
Isolation of CD34+ cells and transduction was performed as described above. 24 hours after transduction the percentage of
CD34+GFP+ cells was determined after Fc blocking and staining with CD34+PE-Cy7 as described above. Cells were harvested
and counted manually with a hemocytometer and trypan blue and resuspended in PBS. In total equivalents of 200,000 CD34+GFP+
cells were transplanted per mouse via retro-orbital injection. A small aliquot was kept in culture for determining the exact number of
transplanted CD34+GFP+ cells 24 hours later. Because the transduction efficiency of experimental group was always lower than in
the control group only absolute percentages of GFP engraftment are illustrated.
Xenotransplantation of transduced CD34+ cells after one week in vitro culture
Isolation of CD34+ cells was performed as described above. After isolation, cells were cultured in StemSpan SFEM exposed to
FLT3L, TPO and SCF each with 100 ng/ml. Then three transduction rounds in a 24 hours time intervals were performed. 24 hours
after the last transduction round cells were cultured for further 96 hours, so that cells were after isolation for one week in vitro cultured
before transplantation.
On the day of transplantation percentage of CD34+GFP+ cells was determined after Fc blocking and staining with CD34+PE-Cy7
as described above. Cells were harvested and counted manually with a hemocytometer and trypan blue and resuspended in PBS. In
total equivalents of 1.5 million of CD34+GFP+ cells were transplanted per mouse via retro-orbital injection under general anesthesia.
Because transduction efficiency of experimental group was always lower than in the control group only absolute percentages of GFP
engraftment are illustrated.
Bleeding of xenotransplanted NSG mice
Beginning 6-weeks after transplantation chimerism in PB was determined in 4-week intervals. Blood samples were taken under gen-
eral anesthesia via retro-orbital bleeding. Blood was lysed with ammonium chloride, washed two times with PBS+BSA 0.2% and
resuspended in 50 ml of PBS+BSA 0.2%. Samples were incubated with Human BD Fc block and CD16/ CD32 Mouse BD Fc blockCell Reports 26, 1906–1918.e1–e8, February 12, 2019 e5
to prevent unspecific binding. After incubation for 10 minutes at room temperature antibody master mix and BV stain buffer was
added and samples were incubated for 20-25 minutes at 4C in the dark. Afterward, cells were washed and resuspended with
PBS+BSA 0.2% containing a viability dye (PI). Samples were analyzed on a BD FACSCanto II.
Bone marrow analysis of NSG mice
Mice were sacrificed and dissected under general anesthesia after the end of the experiment or reaching the human endpoint of the
experiment. Bones (Femur, tibia, fibula and pelvis) were collected and cleaned. Bones were crushed in the presence of PBS+0.2%
PBS with a mortar and pestle. The obtained cell suspension was filtered through a 40 mm filter. Remaining erythrocytes were lysed
with ammonium chloride. Cells were then pelleted by centrifugation and resuspended in PBS+BSA 0.2%. For preventing unspecific
binding samples were incubated with Human BD Fc block and CD16/ CD32 Mouse BD Fc block.
After incubation for 10 minutes at room temperature, antibody master mix and BV stain (only for lineage-specific staining) buffer
was added and samples were incubated for 20-25 minutes at 4C in the dark. Afterward, cells were washed and resuspended with
PBS+BSA 0.2% containing a viability dye (PI). Samples were analyzed on a BD FACSCanto II (Lineage staining) and LSRII (progenitor
staining).
RNA-Seq of CD34+ cells
100,000 GFP+ CD34+ cells were sorted into lysis buffer 4 days post-transduction. RNA was extracted using the Nucleospin RNA XS
Kit, with the addition of a second elution step to increase yield. RNA quality and quantity was assessed using the Bioanalyzer RNA
total Pico Assay. RNA samples with an RNA-integrity > 8 were processed for RNA-seq library preparation using the SMARTer
Stranded Total RNA-seq Kit. Briefly, 10 ng of total RNA was reverse transcribed using random primers and amplified via PCR during
which barcoded Illumina adapters were added. After amplification, ribosomal RNA and mitochondrial cDNA were removed by
annealing specific R-probes, resulting in cleavage of ribosomal and mitochondrial cDNA in the presence of ZapR. After cleavage
of ribosomal and mitochondrial cDNA, the remaining cDNA was amplified again during another round of PCR. The nM concentration
of RNA-seq libraries were quantified based on library size (Bioanalyzer) and cDNA concentration (Qubit) and normalized to 2nM prior
to pooling. RNA-sequencing was performed on an Illumina HiSeq 2500machine, three single-end runs with a read length of 63-64nt,
resulting in fastq samples consisting of 26 to 64 million reads. Sample mapping was done with STAR (version 2.5.1b-2.5.2b), a
custom genome index was build using Genecodegenes.org release 24 (GRCh38.p5) Ensembl 83, December 2015. STAR outputs
read counts per gene, these where filtered by removing ribosomal and transfer RNA. Differential expression (DE) analyses by EdgeR
(version 3.16.2), with upper quartile normalization. DE genes per condition ranked by p value and adjusted for multiple testing using a
Benjamini- Hochberg method. The final DE gene lists were filtered by FDR < 0.05.
The RNA-seq data are deposited at ENA (PRJEB22831).
Gene Annotation and GO search was done using String database (https://string-db.org). Corresponding annotated and GO files
were downloaded from the site and further analyzed with custom scripts. GOChord plots were done in R (GOplot packages).
RNA expression data from Laurenti et al., (2013), were obtained from GEO (GSE42141). Expression heatmap was done using R
using heatmap.2 function in gplot library. Data were clustered by correlation and z-transformed. Gene Set-Enrichment Analysis
was performed on a preranked list of all differentially expressed genes (FDR < 0.1). The number of permutations was set to 1000,
with exclusion of filtersets < 10. (Furthermore, we applied the following filters scoring_sheme weighted, norm meandiv, make_sets
true, gui false, set_max 500, set_min 15, npmerm 1000)
Chip-Seq of transduced CD34+ cells
Frozen human CD34+ enriched cord blood cells were thawn, pooled (Batch 1 = 21 cords, Batch 2 = 21 cords, Batch 3 = 31 cords) and
cultured in StemSpan SFEM with TPO, SCF and FLT3L (each 100 ng/ml) for prestimulation. After 24 – 48 hours three transduction
rounds with retroviral supernatant for either EV or CBX7 at 24-hour time intervals were performed. Transduction was performed
as described above. After the final transduction round, cells were further expanded in StemSpan SFEM with TPO, SCF and
FLT3L (each 100 ng/ml). One week after thawing, cells were stained and CD34+GFP+ cells sorted as described above. Sorted cells
were washed in ice-cold PBS+BSA 0,2%, centrifuged (450G, 5 min, 4C) and resuspended in 1% cold formaldehyde for fixation.
Tubes were incubated on a rotator at 4C for 10 minutes. Fixation was stopped by adding glycine to a final concentration of
0.125M. After addition of glycine cells were incubated on a rotator at 4C for 5 minutes, washed two times with cold PBS, transferred
to a low-adherent tube and resuspended in SDS buffer (NaCl 100mM, Tris-Cl pH8.1 50 mM, NaN3 0.2%, 0.5% SDS) + cOmplete
protease inhibitors (1 tablet/ 50 mL SDS buffer). Samples were snapfrozen on dry ice and then transferred to 80C for storage.
The following table describes the number of transduced CD34+ cells/ experiment and per antibody in million of cells.H3K9me3 H3K27me3 CBX7 IgG
1st Experiment 1.4 1.4 2 0.2
2nd Experiment 0.65 0.8 0.8 0.125
3rd Experiment 1 1 2 0.2
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For chromatin-immunoprecipitation, samples were thawn, centrifuged for 5 minutes at 900 g at room temperature and the super-
natant was discarded. Pellets were resuspended in 500 ml of IP buffer (30mL SDS buffer + 15mL Triton dilution buffer (100mMTris-Cl
pH8.6 + 100mM NaCl + 5mM EDTA ph 8.0 + 0.2% NaN3 + 5%Triton X-100 + cOmplete protease inhibitors) and sonicated to an
average length of 400-500 bps (Bioruptor 30 s on/ 30 s off / cycle, high, in total 3 cycles). 5%of each sample was reversed crosslinked
in TE with 1% SDS and 200 mM NaCl overnight at 65C. On the next day decrosslinked DNA was isolated with the QIAquick PCR
purification kit (QIAGEN) and appropriate fragment length was confirmed via agarose gel electrophoresis.
Protein A/G magnetic beads were washed three times with cold PBS and once with cold IP buffer. Crosslinked and fragmented
samples were thawn and centrifuged for 30 min at 17,000 g at 4C. Samples were precleared by rotating at 4Cwith 7.5 ml of washed
beads for 1 hour. Samples were then distributed into several low adherence tubes for incubation with 5 mg of antibody and incubated
overnight at 4C on a rotating platform. The next day, samples were incubated with 20 ml of washed beads for 4 hours on a rotating
platform at 4C. Using a magnetic stand, the supernatant was removed and beads were washed 4x in a low salt buffer (150 mM) and
once with TE. After the last washing step samples were incubated in 1% SDS, 200 nM NaCl overnight at 65C with 1100 RPM to
reverse crosslinks. DNA was isolated with QIAquick PCR purification kit and enrichment of positive and negative loci was confirmed
via qPCR.
ChIP libraries for sequencing were prepared with the Microplex Library Preparation Kit V2 (Diagenode, C05010012) according to
the manufacturers protocol. The concentration of individual Chip-seq samples was determined based on library size (Agilent, Bio-
analyzer 2100) and DNA concentration (Thermo Fisher, Qubit) and diluted to 2nM prior to pooling.
ChIP-Seq was performed on an Illumina NextSeq 500 machine, paired-end 79-80 bp, a custom genome index was build using
Genecodegenes.org release 25 (GRCh38.p7) Ensembl 85, July 2016. BAMmem (version 0.7.15) produced BAM files were generated
and processed with Samtools (version 1.3.1). MACS2 (version 2.1.0) with the settings -f BAMPE –-nomodel –-broad –broad-cutoff -g
2.7e9 –kep-dup 1. The output BED files where analyzed using bedtools (version 2.26.0) functions intersect, closest and Deeptools
(version 2.4.2).
The Chip-seq data are deposited at ENA (PRJEB22344).
Mass spectrometry of pull-downs of FLAG-tagged huCBX7, huCBX8, huCBX4andGFP inK562 cells and FLAG-tagged
muCbx7 and GFP in 32d-cells
32D cells and K562 cells were transduced as described above, sorted and expanded. Cells were harvested and washed. For each
experiment 2-4 mL of cell pellets were used. Cell pellets were resuspended in 4-5 pellet volumes of ice-cold buffer A (10mM HEPES
ph 7.6, 1.5mM MgCl2 and 10mM KCl, 0.5 mM DTT+ complete protease inhibitor), lysed for 10 minutes on ice and centrifuged for
10 min at 3000 rpm. Pellets were resuspended in 2 pellet volumes of buffer A. The cell suspension was homogenized with a Dounce
Homogenizer with 10 strokes (pestle A). The homogenized suspension was centrifuged for 10 minutes with 3000 rpm. Supernatant
was removed and pellets were centrifuged for 1 minute with 3000 rpm. Supernatant was removed and pellets were resuspended in
1.5 pellet volumes of buffer C (20 mMHEPES ph 7.6, 20% glycerol, 420 mMNaCl, 1.5 mMMgCl2, 0.2 mM EDTA, 0.5 mMDTT, com-
plete protease inhibitor). Nuclei suspension was homogenized with Dounce homogenizer with 10 strokes (pestle B). The suspension
was then rotated on a rotor suspension at 4C for 30 minutes and afterward centrifuged for 15 min with maximal speed. Nuclear ex-
tracts were dialyzed with a SnakeSkin Dialysis tube to buffer D (20 mM HEPES [pH 7.6], 0.2 mM EDTA, 1.5 mMMgCl2, 100 mM KCl,
20% glycerol, 0,5 mM DTT, 0.2 mM PMSF, 9.5 mg/l sodium Metabisulfite).
60 mL of anti-FLAG M2 agarose beads (Sigma) equilibrated and washed in buffer C-100 (20 mM HEPES ph 7.6, 20% glycerol,
1.5 mMMgCl2, 100 mMKCl, 0.2 mMEDTA, 0,02%NP40, 0.5 mMDTT, complete proteaseinhibitor) were added to 1.5 mL of nuclear
extract in low-adherencemicrocentrifuge tubes and incubated for 3 hr at 4C in the presence of 225 units of Benzonase (Novagen) on
a rotator. Afterward beads were washed 5-times with buffer C-100. Bound proteins were eluted four times with 60 ml of 3xFLAG-pep-
tide solution (buffer c-100 + 0.2 mg/ml 3xFLAG peptide) for 15 minutes at 4C. Efficiency of co-immunoprecipitation and elution was
checked via western blot with staining against FLAG. Most efficient elutions were pooled, TCA precipitated, and proteins separated
by polacrylamide gel electrophoresis stained with (Invitrogen). MS was done in a label free format. For each identified peptide and
protein spectral counts were calculated using commercial PEAK studio software, using standard filtering settings. Further, data were
merged for all 10 slices into a single table, the sumof all spectral counts (per slice) was taken as ameasure of the protein amount in the
sample. Data were grouped into three experiments (Human, mouse 1 and mouse 2), sorted by spectral count abundance. The last
10%of the least abundant proteins were removed from each pull down list. The rest of the proteins were ranked in relative scale (0 for
themost abundant to 0.9 as the least abundant). The cumulative abundance rank index was calculated for every candidate protein by
subtracting each abundance rank index from the control rank index (GFP).
The list of proteins with K-Me3 modifications was downloaded from Phosphosite database. Information for proteins abundance
was downloaded from PaxDB site average abundance across all human samples was used for this analysis.
Cross comparison of the gene/protein lists from different databases was done using custom scripts. All illustrations were prepared
in R and Python using standard graphic packages.
For identification of trimethylated interaction partners of CBX7 we only considered proteins which were in the top 20% of the
relative ranked ordered CBX7-binding proteins and which have an abundance score below 100 (ppm) over all cell types and whose
relative ranked score in the experimental sample is higher than in the control sample.Cell Reports 26, 1906–1918.e1–e8, February 12, 2019 e7
To confirm interaction of CBX7 andSETDB1 in K562 cells we performedCo-IP in FLAG-taggedCBX7 overexpressing K562 cells as
described above and performed SDS-PAGE. After protein transfer membrane was stained against CBX7 and SETDB1.
Detection of CBX7 and SETDB1 interaction in HL60 cells by DUOLINK in situ proximity ligation assay (PLA)
53 104 HL60 cells were fixed in ice-coldmethanol for 5minutes on cytospin slides. Interaction of the endogenous CBX7 andSETDB1
proteins in HL60 cells was assessed using the Duolink in situ Proximity Ligation Assay (PLA) (Olink Bioscience, Uppsala, Sweden), as
described by the manufacturer. Used antibodies:
d Polyclonal rabbit anti human/mouse CBX7 p15 Santa Cruz Biotechnology, SC 70-232
d anti- SETDB1 Antibody (5H6A12) Pierce Protein, MA5-15722
Purification of FLAG-tagged protein
Retroviral supernatant for overexpressing flag-tagged huCBX7 and lentiviral supernatant for overexpressing flag-tagged huSETDB1
was produced as described above. 293FT cells were transduced with two transduction rounds and expanded.
FLAG-tagged SETDB1 and CBX7 was purified using anti-FlagM2magnetic beads (Sigma). Frozen pellets were resuspended in 10
vol (v/v) lysis buffer (50 mM Tris-HCl pH 7.5, 600 mM NaCl, 2 mM EDTA, 1.0% NP40 (v/v), 1:1000 ml Protease Inhibitor Mix (Sigma-
Aldrich). Lysates were incubated for 30min on ice while being inverted (3 times) every 5min. After incubation the lysate was forced 10
times through a 26 g needle. Debris was pelleted by centrifugation (20000 g, 30 min, 4C) and the supernatant transferred to a new
tube. 1 original pellet vol. (v/v) anti-Flag M2 magnetic beads (Sigma-Aldrich) was washed 4 times with 1 mL TBS (50 mM Tris-Cl, pH
7.6; 150 mM NaCl) and 1 time with lysis buffer. The supernatant and the washed beads were combined and antigen capture was
performed for 4 hr at 4C using a head-over-tail rotator (HOT). After incubation, samples were placed on a magnetic stand for
1 min. The supernatant was removed and the bead-bound protein washed 3 times with 1ml lysis buffer (5 min HOT, 1 min magnetic
stand) and 3 times with 1 mL wash buffer (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM EDTA, 0.1% NP40 (v/v)). The FLAG-tagged
protein was eluted by adding 150 ml elution buffer (50 mM Tris-HCl pH 7.5, 150 mMNaCl, 3xFlag-Peptide 1mg/ml) and incubation for
5 hr at 4C. 20 ml 85% glycerol were added to the eluted protein. Proteins were stored at 20C.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details for each experiment are indicated in the legend of each figure, where appropriate. Statistical analyses of mass
spectrometry data is provided in Table S6. Software used is provided in the Key Resource Table.e8 Cell Reports 26, 1906–1918.e1–e8, February 12, 2019
